Advanced Catheter Therapies

Executive Summary

Advanced Catheter Therapies (ACT) is a privately held medical device company based in Chattanooga, Tennessee, focused on revolutionizing targeted drug delivery through its patented Pressana Occlusion Perfusion Catheter (OPC). The OPC creates a localized treatment chamber that isolates a target lesion and enables the infusion of physician-selected therapeutic agents, potentially improving efficacy and reducing systemic side effects in cardiovascular and other disease states. Founded in 2008, ACT has developed a versatile platform applicable to multiple therapeutic areas, including peripheral artery disease, oncology, and infection control. The company's technology addresses a critical need for precision medicine in interventional procedures, offering controlled delivery of drugs, biologics, or gene therapies directly to diseased tissue. ACT operates in the competitive cardiovascular and medical device sectors, but its differentiated approach could capture significant market share if clinical validation is achieved. The company has not yet disclosed its funding history or valuation, suggesting it may be in early commercialization or seeking additional capital. Given the limited public information, the conviction in near-term success is moderate; however, the platform's broad applicability and growing interest in localized therapies present a compelling long-term opportunity. Key upcoming catalysts include progress in clinical trials, FDA regulatory milestones, and potential strategic partnerships to accelerate development and commercialization.

Upcoming Catalysts (preview)

• Q4 2026Initiation of First-in-Human Clinical Trial for OPC in Peripheral Artery Disease60% success
• Q2 2027FDA 510(k) Clearance for Occlusion Perfusion Catheter40% success
• Q1 2027Strategic Partnership or Licensing Agreement with a Major Pharmaceutical or Device Company50% success